Is MESO a Good Stock to Buy? The Bull and Bear Case (2026)
Last updated November 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Mesoblast Limited (MESO) rests on Ryoncil's first full year of sales: Ryoncil generated roughly $115 million of net revenue in the fiscal year ended June 30, 2026, its first complete year on the market, with about $66.5 million of that in the second half. The bear case rests on nearly all current revenue comes from a single product in a single small indication, so any manufacturing interruption, reimbursement change or safety signal on Ryoncil would hit the whole business at once. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
MESO key stats
At $12.45 on November 16, 2026, Mesoblast Limited (MESO) has a market cap of $1.6B.
- Market cap
- $1.6B
- P/E (forward)
- 27.4
- Price to book
- 2.8
- Beta
- 0.91
Market cap, P/E and yield are measured at the $12.45 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Mesoblast Limited (MESO)?
The last two weeks for Mesoblast Limited, as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- MESO closed at $12.45 on November 16, 2026, down 13.8% over the past five trading days (from $14.44).
- On November 16, 2026, Mesoblast Limited filed a current report (6-K) with the SEC. Read the 6-K on sec.gov
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
Mesoblast Limited is a Melbourne-based biopharmaceutical company founded in 2004 by Dr. Silviu Itescu, who still runs it, and it develops allogeneic (off the shelf) mesenchymal stromal cell medicines for severe inflammatory disease. Its lead product, Ryoncil (remestemcel-L-rknd), was approved by the FDA in December 2024 for steroid-refractory acute graft versus host disease in children two months and older, making it the first FDA-approved mesenchymal stromal cell therapy. The regimen is eight intravenous infusions over four weeks at a list price of about $194,000 per infusion, which puts a full course near $1.55 million before rebates, chargebacks and patient assistance. A commercial team of roughly ten representatives sells into about 45 priority transplant centers that handle around 80 percent of U.S. pediatric transplants, and coverage now reaches more than 250 million insured U.S. lives including fee-for-service Medicaid. Mesoblast also earns royalties on TEMCELL, the same cell technology marketed in Japan by licensee JCR Pharmaceuticals, and holds more than 1,000 granted patents and applications running to at least 2044. The investment picture rests on one launched product and several unapproved ones. Ryoncil net revenue climbed from about $11.3 million in the stub quarter after the late-March 2025 launch to roughly $30.3 million in the March 2026 quarter and about $36 million in the June 2026 quarter, for a full-year fiscal 2026 total near $115 million; the company reported its fiscal year results on August 26, 2026, and Yahoo Finance data show a fiscal 2026 net loss of about $80 million, narrower than the roughly $157 million loss a year earlier. Gross margin is high, with cost of sales of about $7.6 million against roughly $48.7 million of product sales in the December 2025 half, but research and development of about $46.2 million and selling and administrative costs of about $28.5 million in that same half keep the company loss-making. At roughly $13.47 per ADS on October 16, 2026 the market value is close to $1.75 billion, or about 15 times fiscal 2026 Ryoncil revenue, which prices in adult graft versus host disease, chronic low back pain and other indications that have not yet been approved. Ordinary shares outstanding roughly doubled between mid-2022 and mid-2025, so dilution has been a persistent feature of how this company funds itself. In September 2026 the FDA approved a new potency assay used to release and monitor all new commercial Ryoncil lots, a manufacturing step that supports supply as production scales and moves to new facilities.
The bull case for MESO
1. Ryoncil's first full year of sales
Ryoncil generated roughly $115 million of net revenue in the fiscal year ended June 30, 2026, its first complete year on the market, with about $66.5 million of that in the second half. Sequential quarters of roughly $30.3 million and $36 million show the ramp continuing rather than flattening after the initial stocking period. Management has described revenue as running ahead of its own launch projections. Analysts tracked by Yahoo Finance expect revenue of about $55 million in the September 2026 quarter and about $267 million for fiscal 2027, which would require the ramp to keep accelerating. The FDA's September 24, 2026 approval of a new potency assay for releasing commercial lots supports manufacturing capacity behind that growth.
2. Label extension into adult graft versus host disease
The approved label covers children only, while the adult steroid-refractory acute GvHD population is roughly three times larger. A registration trial in adults is enrolling, with up to 40 U.S. sites expected to activate that together cover about 60 percent of the roughly 8,500 annual adult allogeneic bone marrow transplants in the United States. Because the manufacturing, sales force and payer coverage already exist, incremental adult volume would flow through a commercial base that is largely built.
3. Rexlemestrocel-L reaching regulatory and trial milestones
Mesoblast received a BLA filing number from the FDA and requested modular review for rexlemestrocel-L in preventing gastrointestinal bleeding in end-stage heart failure patients with a left ventricular assist device, an orphan-designated indication. Separately, the MSB-DR004 registrational Phase 3 trial in chronic low back pain reached its target of at least 300 treated patients in July 2026, and those patients will be followed to a twelve-month pain endpoint. A second and third approved product would change the revenue base materially.
4. A repaired capital structure
In June 2026 Mesoblast drew $50 million from a five-year facility provided by existing shareholder and director Dr. Gregory George, retiring the higher-cost NovaQuest debt and eliminating its near-term maturities. Cash stood at about $103 million at June 30, 2026, and net operating cash spend for fiscal 2026 was roughly $43.8 million, down to about $13.4 million in the second half as product revenue offset spending. The facility is secured against the TEMCELL royalty stream rather than issued as equity, so it did not dilute holders.
The bear case for MESO
Nearly all current revenue comes from a single product in a single small indication, so any manufacturing interruption, reimbursement change or safety signal on Ryoncil would hit the whole business at once. The adult GvHD, chronic low back pain, LVAD-related bleeding and Duchenne muscular dystrophy programs are all unapproved, and Mesoblast has a long history of FDA setbacks, including the 2020 complete response letter that preceded a four-year delay to approval. Ordinary shares roughly doubled from about 650 million in mid-2022 to about 1.28 billion in mid-2025, and the company has said it will need additional capital beyond the next twelve months, so further dilution is a reasonable expectation. Book equity of about $575 million at December 31, 2025 is almost entirely intangible assets and goodwill at roughly $569 million, which means the price-to-book ratio understates how little tangible net asset backing there is. Prior management guidance and pipeline timelines have slipped repeatedly, and the share price reflects that skepticism: the ADS fell about 18% over the three months to October 16, 2026 and about 26% year to date, to near its 52-week low of about $13.05. Debt of about $127 million sits against roughly $103 million of cash.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding MESO already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on MESO
Too few analysts publish on MESO for a consensus target to mean anything, so there is no professional average to weigh against your own view. That cuts both ways: less informed opinion to lean on, and less of it already priced in. The MESO forecast page covers what coverage does exist.
How is MESO valued?
Market cap, P/E and dividend yield at today's price are in the MESO key stats above. The business figures below come from Mesoblast Limited's reported results as of October 2026 and change when it next reports.
- Ryoncil net revenue (FY2026, year to June 30, 2026): ~$115M
- Revenue (TTM, per Yahoo Finance): ~$120M; price to sales ~14.5x
- Net loss (FY2026): ~$80M, vs ~$157M in FY2025
- Gross / operating margin: ~80% / about -33%
- Net operating cash spend (FY2026): ~$43.8M
- Cash and debt: ~$103M cash, ~$127M debt at June 30, 2026
As of October 2026: Mesoblast reports in U.S. dollars under IFRS even though the parent company's functional currency is the Australian dollar, and its fiscal year ends June 30, so figures quoted as fiscal 2026 cover July 2025 through June 2026. At about $13.47 per ADS on October 16, 2026, the stock trades near 14 to 15 times trailing revenue, down from about 17 times in August as the price fell. Analyst coverage is thin: two analysts in Yahoo Finance's data, with consensus expecting a small loss for fiscal 2027 and a first profit (about $0.46 per ADS) in fiscal 2028.
How do you decide if MESO is a buy?
Whether MESO is a buy is easier to judge through four narrower questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold MESO indirectly through an index or sector ETF before adding more.
What would change your mind on MESO
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: Ryoncil's first full year of sales stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
- Bear case breaks if: nearly all current revenue comes from a single product in a single small indication, so any manufacturing interruption, reimbursement change or safety signal on Ryoncil would hit the whole business at once fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the MESO stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about MESO against your real portfolio and see your actual exposure before deciding.
Your questions about Mesoblast Limited
Ask Walnut's AI anything about MESO and see how it fits what you own.
FAQ
Is MESO a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on Ryoncil's first full year of sales, with ryoncil net revenue (fy2026, year to june 30, 2026) at ~$115M. The bear case rests on nearly all current revenue comes from a single product in a single small indication, so any manufacturing interruption, reimbursement change or safety signal on Ryoncil would hit the whole business at once. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.
Should I sell MESO?
+
Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Nearly all current revenue comes from a single product in a single small indication, so any manufacturing interruption, reimbursement change or safety signal on Ryoncil would hit the whole business at once. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. Walnut is not an investment adviser.
What is the bull case for MESO?
+
Ryoncil's first full year of sales. Ryoncil generated roughly $115 million of net revenue in the fiscal year ended June 30, 2026, its first complete year on the market, with about $66.5 million of that in the second half.
What is the bear case for MESO?
+
Nearly all current revenue comes from a single product in a single small indication, so any manufacturing interruption, reimbursement change or safety signal on Ryoncil would hit the whole business at once. The adult GvHD, chronic low back pain, LVAD-related bleeding and Duchenne muscular dystrophy programs are all unapproved, and Mesoblast has a long history of FDA setbacks, including the 2020 complete response letter that preceded a four-year delay to approval. Ordinary shares roughly doubled from about 650 million in mid-2022 to about 1.28 billion in mid-2025, and the company has said it will need additional capital beyond the next twelve months, so further dilution is a reasonable expectation. Book equity of about $575 million at December 31, 2025 is almost entirely intangible assets and goodwill at roughly $569 million, which means the price-to-book ratio understates how little tangible net asset backing there is. Prior management guidance and pipeline timelines have slipped repeatedly, and the share price reflects that skepticism: the ADS fell about 18% over the three months to October 16, 2026 and about 26% year to date, to near its 52-week low of about $13.05. Debt of about $127 million sits against roughly $103 million of cash.
What does Mesoblast Limited do?
+
Melbourne-based cell-therapy company selling Ryoncil, the first FDA-approved mesenchymal stromal cell therapy for steroid-refractory graft-versus-host disease in children.
What would have to change for MESO to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Ryoncil's first full year of sales) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (nearly all current revenue comes from a single product in a single small indication, so any manufacturing interruption, reimbursement change or safety signal on Ryoncil would hit the whole business at once) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does Mesoblast do, and what is Ryoncil?
+
Mesoblast develops allogeneic, or off the shelf, mesenchymal stromal cell medicines that dampen severe inflammation. Ryoncil (remestemcel-L-rknd) is its one approved product, cleared by the FDA in December 2024 for steroid-refractory acute graft versus host disease in children two months and older. It was the first mesenchymal stromal cell therapy ever approved in the United States, and it is given as eight intravenous infusions over four weeks.
What is the difference between MESO on Nasdaq and MSB on the ASX?
+
They are claims on the same company. MSB is the Australian Securities Exchange line in ordinary shares and Australian dollars, and it is the primary listing. MESO is the Nasdaq ADS line in U.S. dollars, with each ADS backed by ten ordinary shares held by a depositary bank. Most U.S. brokers, including those Walnut connects to, will only offer the MESO line, and the depositary charges periodic fees against ADS holders.
Walnut is informational, not investment advice, and gives no verdict on MESO. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. The share price is the last one Yahoo Finance reported on November 16, 2026. Verify current figures with your broker before acting on them.